Greg Yothers1, Alan P Venook2, Eiji Oki3, Donna Niedzwiecki4, Yan Lin1, Michael R Crager5, Calvin Chao6, Frederick L Baehner2,7, Norman Wolmark1, Takayuki Yoshino8. 1. NSABP, NRG Oncology, University of Pittsburgh, Pittsburgh, PA, USA. 2. Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA, USA. 3. Department of Surgery and Science, Kyushu University, Kyushu, Japan. 4. Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA. 5. Department of Biostatistics, Precision Oncology, Exact Sciences Corporation, Redwood City, CA, USA. 6. Global Medical Affairs, Precision Oncology, Exact Sciences Corporation, Redwood City, CA, USA. 7. Medical Department, Precision Oncology, Exact Sciences Corporation, Redwood City, CA, USA. 8. National Cancer Center Hospital East, Kashiwa, Japan.
Abstract
Background: Individualized estimates of the risk of recurrence in colon cancer patients are needed that reflect current medical practice and available treatment options. Methods: Three validation studies of the 12-gene colon recurrence score assay were used with pre-specified patient-specific meta-analysis (PSMA) methods to integrate the 12-gene Oncotype DX Colon Recurrence Score result (RS) with the clinical and pathology risk factors stage, T-stage, mis-match repair (MMR) status, and number of nodes examined to calculate individualized recurrence risk estimates. Baseline risk estimation used the most recent studies, so the risk estimates reflect current medical practice. The effect of fluorouracil (5FU) was estimated with a meta-analysis of two studies. The effect of oxaliplatin was estimated using one of the RS assay validation studies, in which patients were randomized to 5FU with or without oxaliplatin. Results: The RS result and each of the clinical-pathologic factors provided independent prognostic information for recurrence. Among stage II, T3, MMR-proficient patients with ≥12 nodes examined (the most common scenario), patients with RS ≤30 (approximately 48%) have estimated 5-year recurrence risk ≤10% with surgery alone. Among stage IIIA/B, T3, MMR-deficient patients with ≥12 nodes examined, patients with RS ≤19 (approximately 14%) have an estimated 5-year recurrence risk ≤10% with surgery alone. Among stage IIIA/B, T3, MMR-proficient patients with ≥12 nodes examined, those with RS ≤14 (approximately 6%) have estimated 5-year recurrence risk ≤10% with 5FU alone. Discussion: The PSMA integrates the 12-gene colon RS result with clinical and pathology factors to provide individualized recurrence risk estimates that reflect current medical practice. The risk estimates are in a range that may help inform treatment decisions for a substantial number of stage II and stage III patients. 2022 Journal of Gastrointestinal Oncology. All rights reserved.
Background: Individualized estimates of the risk of recurrence in colon cancer patients are needed that reflect current medical practice and available treatment options. Methods: Three validation studies of the 12-gene colon recurrence score assay were used with pre-specified patient-specific meta-analysis (PSMA) methods to integrate the 12-gene Oncotype DX Colon Recurrence Score result (RS) with the clinical and pathology risk factors stage, T-stage, mis-match repair (MMR) status, and number of nodes examined to calculate individualized recurrence risk estimates. Baseline risk estimation used the most recent studies, so the risk estimates reflect current medical practice. The effect of fluorouracil (5FU) was estimated with a meta-analysis of two studies. The effect of oxaliplatin was estimated using one of the RS assay validation studies, in which patients were randomized to 5FU with or without oxaliplatin. Results: The RS result and each of the clinical-pathologic factors provided independent prognostic information for recurrence. Among stage II, T3, MMR-proficient patients with ≥12 nodes examined (the most common scenario), patients with RS ≤30 (approximately 48%) have estimated 5-year recurrence risk ≤10% with surgery alone. Among stage IIIA/B, T3, MMR-deficient patients with ≥12 nodes examined, patients with RS ≤19 (approximately 14%) have an estimated 5-year recurrence risk ≤10% with surgery alone. Among stage IIIA/B, T3, MMR-proficient patients with ≥12 nodes examined, those with RS ≤14 (approximately 6%) have estimated 5-year recurrence risk ≤10% with 5FU alone. Discussion: The PSMA integrates the 12-gene colon RS result with clinical and pathology factors to provide individualized recurrence risk estimates that reflect current medical practice. The risk estimates are in a range that may help inform treatment decisions for a substantial number of stage II and stage III patients. 2022 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: Richard G Gray; Philip Quirke; Kelly Handley; Margarita Lopatin; Laura Magill; Frederick L Baehner; Claire Beaumont; Kim M Clark-Langone; Carl N Yoshizawa; Mark Lee; Drew Watson; Steven Shak; David J Kerr Journal: J Clin Oncol Date: 2011-11-07 Impact factor: 44.544
Authors: Michael J O'Connell; Ian Lavery; Greg Yothers; Soonmyung Paik; Kim M Clark-Langone; Margarita Lopatin; Drew Watson; Frederick L Baehner; Steven Shak; Joffre Baker; J Wayne Cowens; Norman Wolmark Journal: J Clin Oncol Date: 2010-08-02 Impact factor: 44.544
Authors: Donna Niedzwiecki; Monica M Bertagnolli; Robert S Warren; Carolyn C Compton; Nancy E Kemeny; Al Bowen Benson; S Gail Eckhardt; Steven Alberts; Gity N Porjosh; David J Kerr; Anthony Fields; Philippe Rougier; J Marc Pipas; Joel H Schwartz; James Atkins; Mark O'Rourke; Michael C Perry; Richard M Goldberg; Robert J Mayer; Thomas A Colacchio Journal: J Clin Oncol Date: 2011-07-11 Impact factor: 44.544
Authors: Daniel J Sargent; Silvia Marsoni; Genevieve Monges; Stephen N Thibodeau; Roberto Labianca; Stanley R Hamilton; Amy J French; Brian Kabat; Nathan R Foster; Valter Torri; Christine Ribic; Axel Grothey; Malcolm Moore; Alberto Zaniboni; Jean-Francois Seitz; Frank Sinicrope; Steven Gallinger Journal: J Clin Oncol Date: 2010-05-24 Impact factor: 44.544
Authors: Richard Gray; Jennifer Barnwell; Christopher McConkey; Robert K Hills; Norman S Williams; David J Kerr Journal: Lancet Date: 2007-12-15 Impact factor: 79.321
Authors: Romain Cohen; Julien Taieb; Jack Fiskum; Greg Yothers; Richard Goldberg; Takayuki Yoshino; Steven Alberts; Carmen Allegra; Aimery de Gramont; Jean-Francois Seitz; Michael O'Connell; Daniel Haller; Norman Wolmark; Charles Erlichman; Alberto Zaniboni; Sara Lonardi; Rachel Kerr; Axel Grothey; Frank A Sinicrope; Thierry André; Qian Shi Journal: J Clin Oncol Date: 2020-12-23 Impact factor: 44.544